Intimation regarding approval for investments in (i) HCG NCHRI Oncology LLP, wholly owned subsidiary for up to Rs. 98 Crore and (ii) Vizag Hospital and Cancer Research Centre Pvt Ltd (Vizag Hospital), a subsidiary of the Company for up to Rs. 155.66 crore for the acquisition of additional stake of 34% in the equity share capital of Vizag Hospital, directly from the selling shareholders..
HCG · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 0.4 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Healthcare Global Enterprises (HCG) has approved two investments totaling up to Rs. 253.66 Crore, both funded through its recent rights issue. First, it will invest up to Rs. 98 Crore in its wholly owned subsidiary HCG NCHRI Oncology LLP, which operates a 74-bed cancer hospital in Nagpur (FY25 revenue: Rs. 89.80 Crore, profit after tax: Rs. 17.02 Crore), to prepay or repay outstanding borrowings. Second, it will invest up to Rs. 155.66 Crore to buy an additional 34% stake in Vizag Hospital and Cancer Research Centre from existing selling shareholders, taking its holding in that subsidiary from 51% to 85%. Vizag Hospital posted FY25 revenue of Rs. 110.14 Crore and profit after tax of Rs. 18.79 Crore. Both transactions are in cash, require no regulatory approvals, and are expected to close in Q1 FY2027.
Both moves strengthen HCG's control over its cancer-care network and use rights-issue proceeds for inorganic and balance-sheet purposes. For shareholders, this means greater consolidation of subsidiary profits but also higher cash deployment of roughly Rs. 250+ Crore in a short window.